OncoMatch/Clinical Trials/NCT04592211
Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer
Is NCT04592211 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies olaparib+pembrolizumab+paclitaxel for gastric cancer stage iv.
Treatment: olaparib+pembrolizumab+paclitaxel — Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD 1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). Olaparib is a potent PARP inhibitor (PARP1, 2, and 3) that is being developed as a monotherapy as well as for combination with chemotherapy, ionizing radiation, and other anti-cancer agents including novel agents and immunotherapy. Paclitaxel is widely used in breast, lung and gastric cancer with every 3-week or weekly cycle. Various targeted anticancer agents have been investigated with paclitaxel and combination with ramucirumab, a monoclonal anti-VEGFR2 antibody, was approved as a 2nd line treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Biomarker criteria
Allowed: HER2 (ERBB2) amplification
Failed first-line trastuzumab treatment for HER2 positive patients
Disease stage
Required: Stage IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: trastuzumab (trastuzumab) — first-line
Failed first-line trastuzumab treatment for HER2 positive patients
Cannot have received: systemic anti-cancer therapy
Has received prior systemic anti-cancer therapy including investigational agents within 2 weeks prior to allocation.
Cannot have received: radiotherapy
Has received prior radiotherapy within 2 weeks of start of study treatment.
Cannot have received: investigational agent (trastuzumab)
Is currently participating in or has participated in a study of an investigational agent including trastuzumab or has used an investigational device within 4 weeks prior to the first dose of study treatment.
Lab requirements
Cardiac function
left ventricular ejection fraction (lvef) ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify